NR1H4 and fatty liver disease: Emerging evidence suggests that intestine-specific FXR agonists may ameliorate hepatic steatosis through BA modulation, the suppression of hepatic gluconeogenesis, and the promotion of white adipose tissue thermogenesis, independent of hepatic FXR activation (31).